Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Files Shelf Registration to Offer up to $150M

NEW YORK (GenomeWeb News) – Trovagene this week filed a shelf registration with the US Securities and Exchange Commission for the public offering of up to $150 million in securities from time to time.

A spokesperson for the San Diego-based molecular diagnostic firm said the filing is associated with a public offering that the company made in the spring of 2012 when it began trading its stock on the Nasdaq.

Proceeds from any offering associated with this week's filing will go toward general corporate purposes, including working capital, R&D, clinical trial expenses, regulatory efforts, and acquisitions, the company said.

Trovagene separately also said in another SEC document that it has entered into a controlled equity offering sales agreement with Cantor Fitzgerald to offer and sell up to $30 million of its stock through the investment bank.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.